Omarigliptin: A new kind of long acting DPP-4 inhibitor
10.7501/j.issn.1674-6376.2017.01.026
- VernacularTitle:奥格列汀:一种新的长效二肽基肽酶-4抑制剂
- Author:
Hongnan CHEN
;
Ying DENG
;
Xiujuan GUO
;
Guodong HUA
- Keywords:
Omarigliptin;
DPP-4 inhibitor;
oral hypoglycemic agents
- From:
Drug Evaluation Research
2017;40(1):133-137
- CountryChina
- Language:Chinese
-
Abstract:
Diabetes is a kind of metabolic disease characterized by hyperglycemia The oral hypoglycemic agents used currently are required to take every day,which brings inconvenience to patients.Omarigliptin is a small molecule DPP-4 (depeptidyl peptidase-4) inhibitor.The drug is developed by the Merck Co,mainly for the treatment of type two diabetes.The drug only need to be taken once a week,so as to improve the patient's compliance and adherence,thereby improving the therapeutic effect.This article introduces the information of omarigliptin from the aspects of synthesis,pharmacology,pharmacokinetics,and clinical research,which provides valuable information for pharmaceutical workers.
